2 Sports Betting Stocks Wall Street Predicts Will Rally More Than 50%

NASDAQ: CZR | Caesars Entertainment Inc. News, Ratings, and Charts

CZR – The U.S. sports betting industry has achieved significant growth over the past two years thanks to sustained demand from stay-at-home orders and the legalization of sports gambling. And despite several macroeconomic headwinds, Wall Street analysts expect the stocks of fundamentally sound sports betting companies Caesars (CZR) and DraftKings (DKNG) to gain momentum in the near term. Read on.

The U.S. sports betting industry has been growing quickly since the worst of the COVID-19 pandemic because the remote lifestyle drove people to engage in online sports betting. More than 30 states in the U.S. have legalized sports betting post the removal of the federal ban on sports wagering in 2018. Last year, the U.S. commercial gaming industry reached a record of $53 billion in revenue, according to American Gaming Association (AGA).

Concerns revolving around the Fed’s hawkish monetary stance and Russia’s invasion of Ukraine have triggered selloffs in some sports betting stocks. However, with advanced technological innovation and favorable government policies, the sports betting industry is expected to rebound soon. Thus, Wall Street analysts are bullish on the sports betting companies with solid fundamentals.

Given the backdrop, Wall Street analysts expect quality sports betting stocks Caesars Entertainment, Inc. (CZR) and DraftKings Inc. (DKNG) to rally more than 50% in price in the coming months.

Caesars Entertainment, Inc. (CZR)

CZR in Las Vegas operates as a gaming and hospitality company in the U.S. The company operates casinos, dining venues, bars, nightclubs, hotels, and entertainment venues. CZR provides staffing and management services, and online sports betting and iGaming services. It owns, leases, and manages more than 52 domestic properties in 16 states.

On March 9, 2022, CZR launched Caesars Sportsbook, a sport wagering mobile app that is available for download and registration throughout Illinois. This sports wagering product might extend CZR’s consumer reach and boost its business growth.

On Feb. 11, 2022, CZR announced the expansion of Caesars Sportsbook to Washington state by partnering with three casinos. This expansion is expected to expand CZR’s customer base and boost its revenue streams.

In its fiscal year 2021 fourth quarter, ended Dec. 31, 2021, CZR’s net revenues increased 63.5% year-over-year to $2.59 billion. The company’s operating income rose 344% year-over-year to $122 million. CZR’s adjusted EBITDA increased 67% from the year-ago value to $581 million.

The $2.38 billion consensus revenue estimate for its fiscal year 2022 first quarter, ending March 2022 represents a 40% year-over-year growth.

Over the past year, CZR stock has slumped 21.1% in price. However, every one of the 12 Wall Street analysts that rated CZR rated it Buy. The 12-month median price target of $119.50 indicates a 54% potential upside from yesterday’s closing price of $77.59. The price targets range from a low of $100.00 to a high of $183.00.

DraftKings Inc. (DKNG)

DKNG is a Boston-based digital sports entertainment and gaming company that operates in the U.S. and internationally. The company operates through two segments: Business-to-Consumer; and Business-to-Business. DKNG provides online consumer products with fantasy sports, sports betting, and iGaming opportunities. DKNG distributes through various channels, including traditional websites, app downloads, and digital platforms.

In January, DKNG launched Mobile Sportsbook Set in Louisiana and New York. This is expected to enhance its accessibility and adoption potential. The launch might boost the company’s reach and revenues.

In its fiscal 2021 fourth quarter, ended December 31, 2021, DKNG’s revenue increased 46.9% year-over-year to $473.33 million. The company’s net other income amounted to $11.95 million for the fourth quarter.

The $413.27 million consensus revenue estimate for its fiscal 2022, ending March 31, 2022, represents 32.5% year-over-year growth. The company has an impressive earnings surprise history; it surpassed the consensus EPS estimates in three of the trailing four quarters.

DKNG stock has declined 35.3% in price year-to-date. However, the $34.32, 12-month median price target indicates a 93% potential upside from yesterday’s closing price of $17.78. Among 21 Wall Street analysts that rated DKNG, 10 rated it Buy, while 11 rated it Hold. The price targets range from a low of $19.00 to a high of $60.00.


CZR shares were trading at $76.07 per share on Thursday afternoon, down $1.52 (-1.96%). Year-to-date, CZR has declined -18.67%, versus a -11.03% rise in the benchmark S&P 500 index during the same period.


About the Author: Mangeet Kaur Bouns


Mangeet’s keen interest in the stock market led her to become an investment researcher and financial journalist. Using her fundamental approach to analyzing stocks, Mangeet’s looks to help retail investors understand the underlying factors before making investment decisions. More...


More Resources for the Stocks in this Article

TickerPOWR RatingIndustry RankRank in Industry
CZRGet RatingGet RatingGet Rating
DKNGGet RatingGet RatingGet Rating

Most Popular Stories on StockNews.com


Are Stocks in a Rolling Correction?

The S&P 500 (SPY) has been stuck below its highs for quite a while. We have seen a series of sell offs, pullbacks and corrections. And now we just seem to be stuck in a tight trading range whipping back and forth. Steve Reitmeister explains this “rolling correction” situation along with a plan and top stocks to put some profits in your pocket. Read on below...

3 Global Stocks to Buy for International Exposure and Growth

With the U.S. market facing a whirlwind of economic uncertainty and volatile Fed policies, seeking solace in international stocks could be a wise move. Diversifying with picks like Alibaba Group (BABA), Rio Tinto (RIO), and Nokia (NOK) might provide the stability and growth a portfolio needs amid the chaos. Read on…

3 Healthcare Stocks With High Analyst Price Targets

Recent innovations, successful trials, and increased research and development spending in the healthcare sector further boost the sector’s appeal today. Given this momentum, investors might consider investing in stocks with high analyst price targets, such as Pfizer (PFE), Biogen (BIIB), and BioMarin Pharmaceutical (BMRN). Read on…

3 Undervalued Tech Stocks With Strong Fundamentals

The tech sector presents a strong investment opportunity due to rising demand for advanced solutions, digital transformation, and AI-driven innovations. With IT services spending growing and the hardware market expanding, tech stocks show promising growth potential. Therefore, investors should consider strong tech stocks like Box (BOX), Teradata (TDC), and AstroNova (ALOT), which look undervalued at current prices. Read on...

This Stock Market is NO FUN!

The easy breezy profits for this young bull market are fading away fast even as the S&P 500 (SPY_ hovers near the all time highs. Instead we have entered the “No Fun” period for the stock market. But don’t confuse that with no ability to generate profits. Steve Reitmeister shows you how to do that in his latest commentary below...

Read More Stories

More Caesars Entertainment Inc. (CZR) News View All

Event/Date Symbol News Detail Start Price End Price Change POWR Rating
Loading, please wait...
View All CZR News